Using DNA-Typing & Erythrocyte Microparticle Analysis to Detect Blood

Status Recruiting

Clinical Trial Summary

A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

Clinical Trial Description

Homologous blood transfusions (HBT) and autologous blood transfusions (ABT) are abused by athletes to illegally increase their hemoglobin mass and subsequently improve oxygen transport.

Anti-Doping labs use flow-cytometry to detect HBT in cheating athletes, but athletes avoid being tested positive by matching their blood for minor blood groups before transfusion. Recent publications suggest that DNA typing by Capillary Electrophoresis or RT-PCR might be an alternative way to detect this kind of doping in athletes. Unfortunately, no data exist on the clearance of DNA after transfusion of one bag of blood using this methodology.

For the detection of doping with ABT, there is no direct method available and only the biological passport, a longitudinal collection of hematological parameters can indicate doping. Recently RBC Microparticles (RBC-MPs) have been described as a potential biomarker for autologous transfusion. However, also for this methodology, no data on the clearance time of RBC-MPs are available.

Thus, in this World Anti-Doping Agency (WADA) approved and sponsored project. The investigators plan to perform a clinical trial in which six healthy subjects receive an ABT and six healthy subjects or patients a HBT. Blood samples will be collected before and at several time-points after transfusion. For the detection of HBT the samples will be analyzed by the official method (cytometry), and the two genotyping methods (STR and RT-PCR) to compare these different techniques and to see if DNA-typing can replace cytometry.

For the ABT the collected samples will be analyzed for RBC-MPs on a cytometer dedicated for Microparticles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03548766
Study type	Interventional
Source	Hamad Medical Corporation
Contact	Sven C Voss
Phone	0097455481955
Email	svoss@adlqatar.qa
Status	Recruiting
Phase	Phase 3
Start date	September 20, 2018
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00106015` - Diamond Blackfan Anemia Registry (DBAR)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Not yet recruiting	`NCT05983536` - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Completed	`NCT00007371` - Hepatitis C in Clinically Discordant Hemophilic Siblings	N/A
Completed	`NCT00005682` - Aplastic Anemia Epidemiology: Incidence and Case-control	N/A
Completed	`NCT00000587` - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection	Phase 2
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04600609` - Examining the Experiences of Children With Blood Disorders
Not yet recruiting	`NCT05305534` - QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
Not yet recruiting	`NCT03881917` - Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
Completed	`NCT00005556` - Retention of Bone Marrow Donors in a National Registry	N/A
Completed	`NCT00000597` - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders	Phase 3
Completed	`NCT03586180` - Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Recruiting	`NCT03848962` - Collection and Distribution of Biospecimens for Novel Research Uses
Not yet recruiting	`NCT04806347` - Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping — Transfusion

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms